NCT06843148 Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
| NCT ID | NCT06843148 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Université de Sherbrooke |
| Condition | Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2026-04 |
| Primary Completion | 2030-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2026-04 with a primary completion date of 2030-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis. MASLD results from fat being disproportionately deposited in the liver. The goal of this mechanistic study is to investigate metabolic response in patients aged 50 to 80 years with non-alcoholic fatty liver disease, after niacin (vitamin B3) treatment. The main questions it aims to answer are: * Does Niacin lower the fat deposition in the liver? * Does Niacin raise White Adipose Tissue storage of dietary fatty acids? Researchers will compare Niacin to a placebo (a look-alike substance that contains no drug) to compare the metabolic response. Duration of study per participant: Up to 28 weeks
Eligibility Criteria
Inclusion Criteria: * aged 50 to 80 years; * diagnosed with MASLD, defined as the presence of liver steatosis + abdominal obesity (as defined by the International Diabetes Federation country/ethnic group-specific criteria; * all women will be post-menopausal. Exclusion Criteria: 1. Presence of advanced fibrosis (i.e., ≥ F3 based on liver stiffness \> 10kPa) using vibration-controlled transient elastography (FibroScan), serum ALT \> 3 times the normal upper limit, or signs of portal hypertension \[106-109\]. 2. Other hepatic disease. 3. Previous diagnosis of diabetes. 4. Overt cardiovascular or renal disease, cancer (other than non-melanoma skin cancer), or other uncontrolled medical conditions. 5. Any contraindication to MRI. 6. Previous intolerance or allergy to nicotinic acid. 7. Having participated to a research study with exposure to radiation in the last two years before the start of the study. 8. Being allergic to eggs 9. Smoking (\>1 cigarette/day) and/or consumption of \>2 alcoholic beverages per day.
Contact & Investigator
André Carpentier, MD
PRINCIPAL INVESTIGATOR
Université de Sherbrooke
Frequently Asked Questions
Who can join the NCT06843148 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06843148 currently recruiting?
Yes, NCT06843148 is actively recruiting participants. Contact the research team at frederique.frisch@usherbrooke.ca for enrollment information.
Where is the NCT06843148 trial being conducted?
This trial is being conducted at Sherbrooke, Canada.
Who is sponsoring the NCT06843148 clinical trial?
NCT06843148 is sponsored by Université de Sherbrooke. The principal investigator is André Carpentier, MD at Université de Sherbrooke. The trial plans to enroll 36 participants.